TW202448925A - 與艱難梭菌結合之抗體 - Google Patents

與艱難梭菌結合之抗體 Download PDF

Info

Publication number
TW202448925A
TW202448925A TW113117444A TW113117444A TW202448925A TW 202448925 A TW202448925 A TW 202448925A TW 113117444 A TW113117444 A TW 113117444A TW 113117444 A TW113117444 A TW 113117444A TW 202448925 A TW202448925 A TW 202448925A
Authority
TW
Taiwan
Prior art keywords
antibody
light chain
heavy chain
sequence number
amino acid
Prior art date
Application number
TW113117444A
Other languages
English (en)
Chinese (zh)
Inventor
新藏礼子
玉野竜太郎
高橋慧崇
Original Assignee
國立大學法人東京大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2023/018019 external-priority patent/WO2023219175A1/ja
Application filed by 國立大學法人東京大學 filed Critical 國立大學法人東京大學
Publication of TW202448925A publication Critical patent/TW202448925A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW113117444A 2023-05-12 2024-05-10 與艱難梭菌結合之抗體 TW202448925A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/JP2023/018019 WO2023219175A1 (ja) 2022-05-13 2023-05-12 炎症性腸疾患（ｉｂｄ）を治療または診断する方法および組成物
WOPCT/JP2023/018019 2023-05-12
JP2023131537 2023-08-10
JP2023-131537 2023-08-10

Publications (1)

Publication Number Publication Date
TW202448925A true TW202448925A (zh) 2024-12-16

Family

ID=93519712

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113117444A TW202448925A (zh) 2023-05-12 2024-05-10 與艱難梭菌結合之抗體

Country Status (5)

Country Link
EP (1) EP4711462A1 (https=)
JP (1) JPWO2024237217A1 (https=)
CN (1) CN121127591A (https=)
TW (1) TW202448925A (https=)
WO (1) WO2024237217A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5916946B2 (ja) * 2013-03-11 2016-05-11 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法
CA3224497A1 (en) 2021-07-01 2023-01-05 Reiko SHINKURA Antibody binding to clostridium difficile
US20240417450A1 (en) * 2021-07-02 2024-12-19 The University Of Tokyo Monoclonal antibody-containing composition for suppressing clostridium difficile bacteria

Also Published As

Publication number Publication date
EP4711462A1 (en) 2026-03-18
CN121127591A (zh) 2025-12-12
WO2024237217A1 (ja) 2024-11-21
JPWO2024237217A1 (https=) 2024-11-21

Similar Documents

Publication Publication Date Title
JP5916946B2 (ja) モノクローナルＩｇＡ抗体の製造方法
JP7405386B2 (ja) クロストリジウム・ディフィシル菌に結合する抗体
JP7430946B2 (ja) クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物
US11718661B2 (en) Composition for the treatment of antibody deficiencies
TW202448925A (zh) 與艱難梭菌結合之抗體
US20250313613A1 (en) Method and composition both for treating or diagnosing inflammatory bowel disease (ibd)
US20250051426A1 (en) Composition containing monoclonal antibody
CN107459575B (zh) 具有抑制病原体的免疫抑制功能的单克隆抗体，其抗原结合片段，以及产生该抗体的杂交瘤
US20250002581A1 (en) Humanized monoclonal antibody for restoring dysfunctional human t and b cells against cancer and viral infection
TW202608478A (zh) 微生物與抗體之組合及用途
WO2025134928A1 (ja) 結腸直腸がんを治療するための組成物
WO2025225737A1 (ja) 微生物と抗体の組み合わせおよび使用